At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Teva Pharmaceutical Industries received FDA approval for Weltruza, a once-monthly injectable treatment for adults with schizophrenia. The drug is the…

Teva received FDA approval for WELTRUZA, a once-monthly subcutaneous olanzapine injection for adults with schizophrenia, with U.S. launch expected.

Teva stock stood at USD 41.62 on October 9, 2026, up 6.0 percent. Its 52-week high is USD 42.02 and

Decision by Royal College of Pharmacy to end sponsorship comes after concerns over Teva Pharmaceuticals’ ‘activities’

Teva Pharmaceutical Industries (TEVA) has an average rating of buy and mean price target of $46.73,

WELTRUZA ™ (olanzapine) for extended-release injectable suspension is the first and only once-monthly subcutaneous long-acting injectable (LAI) formulation of olanzapine for the treatment of schizophrenia in adults with no loading doses, no oral supplementation and no post-injection monitoring required The approval is based on results from the pivotal Phase 3 SOLARIS trial, which demonstrated overall symptom improvement, significant reduction in illness severity and improvement in personal and social functioning, with a systemic safety profile consistent with oral olanzapine 1 As Teva drives forward its Pivot to Growth strategy, the company continues to deliver on its commitment to patient-centered innovation in neuroscience, including a differentiated long-acting injectable franchise Teva will hold an investor call and live webcast on Friday, October 9, 2026, 8:00 a.m. ET PARSIPPANY, N.J. and TEL AVIV, Israel, Oct. 09, 2026 (GLOBE NEWSWIRE) - Teva Pharmaceuticals, a U.S.

2026-10-09. The following slide deck was published by Teva Pharmaceutical Industries Limited in conjunction with this event.

Teva Pharmaceutical Industries (NYSE:TEVA) Sets New 52-Week High - What

FDA approved Teva's monthly WELTRUZA for adults with schizophrenia; three strengths are expected in the U.S. in the coming weeks.